Galapagos Nv Revenue Growth Rates (GLPG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Galapagos Nv  (NASDAQ: GLPG)
 

GLPG's Revenue Growth by Quarter and Year

Galapagos Nv's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GLPG Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 1,245.72
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 1,245.72

GLPGs Annual Revenue
Galapagos Nv's Revenue in the fiscal year 2025 $ 1,245.72 millions
Galapagos Nv's Revenue in the fiscal year 2024 $ 308.73 millions
Galapagos Nv's Revenue in the fiscal year 2023 $ 268.49 millions
Galapagos Nv's Revenue in the fiscal year 2022 $ 565.91 millions
Galapagos Nv's Revenue in the fiscal year 2021 $ 543.03 millions




GLPG Revenue fourth quarter 2025 Y/Y Growth Comment
Galapagos Nv achieved in the fourth quarter 2025, above Company average Revenue surge of 303.5% year on year, to $ 1,245.72 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 95 other companies have achieved higher Revenue growth. While Galapagos Nv' s Revenue doubling of 303.5% ranks overall at the positon no. 1778 in the fourth quarter 2025.


GLPG Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 303.5 % 14.99 % -52.56 % 4.21 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   303.5 % 14.99 % -52.56 % -

Financial Statements
Galapagos Nv's fourth quarter 2025 Revenue $ 1,245.72 millions GLPG's Income Statement
Galapagos Nv's fourth quarter 2024 Revenue $ 308.73 millions Quarterly GLPG's Income Statement


GLPG Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   303.5 % 14.99 % -52.56 % -


Back to GLPG Growth rate Comparisons >> Back to GLPG Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #96
Healthcare Sector #285
Overall #1778

Revenue Y/Y Growth Statistics
High Average Low
192.55 % 20.44 % -52.56 %
(Dec 31 2019)   (Dec 31 2023)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #96
Healthcare Sector #285
Overall #1778
Revenue Y/Y Growth Statistics
High Average Low
192.55 % 20.44 % -52.56 %
(Dec 31 2019)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Galapagos Nv's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GLPG's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GLPG's IV. Quarter Q/Q Revenue Comment


Galapagos Nv's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 1,245.72 $ 308.73 $ 268.49 $ 565.91 $ 543.03
Y / Y Revenue Growth (TTM) 303.5 % 14.99 % -52.56 % 4.21 % 1.42 %
Year on Year Revenue Growth Overall Ranking # 1778 # 0 # 1873 # 0 # 0
Seqeuential Revenue Change (TTM) 303.5 % 14.99 % -52.56 % 4.21 % 1.42 %
Seq. Revenue Growth (TTM) Overall Ranking # 1778 # 0 # 1873 # 0 # 0


Cumulative Revenue growth Comment
Galapagos Nv saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 303.5% year on year, to $ 1,246 millions if the fiscal year would have ended in Dec 31 2025.
Galapagos Nv's trailing twelve months Revenue growth was higher than company's average 20.44% and higher than 14.99% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 303.5 % increase from $308.73 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 284 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1778.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 96
Healthcare Sector # 285
Overall # 1778

Revenue TTM Y/Y Growth Statistics
High Average Low
192.55 %
 20.44 %
-52.56 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 96
Sector # 285
S&P 500 # 1778
Cumulative Revenue growth Comment
Galapagos Nv saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 303.5% year on year, to $ 1,246 millions if the fiscal year would have ended in Dec 31 2025.
Galapagos Nv's trailing twelve months Revenue growth was higher than company's average 20.44% and higher than 14.99% growth in Dec 31 2024.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 303.5 % increase from $308.73 millions in the period from Dec 31 2024 to Dec 31 2021.

In the Healthcare sector 284 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1778.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 96
Healthcare Sector # 285
Overall # 1778

Revenue TTM Y/Y Growth Statistics
High Average Low
192.55 %
20.44 %
-52.56 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 96
Sector # 285
S&P 500 # 1778




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GLPG's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Seastar Medical Holding Corp526.87%$ 526.866 millions
Assembly Biosciences Inc 477.26%$ 477.260 millions
Renovorx Inc 453.49%$ 453.488 millions
Legend Biotech Corporation451.62%$ 451.624 millions
Capforce Inc 424.00%$ 424.000 millions
Altimmune inc 420.00%$ 420.000 millions
Vir Biotechnology Inc 417.78%$ 417.779 millions
Cg Oncology Inc 409.21%$ 409.211 millions
Immunitybio inc 406.95%$ 406.952 millions
Aspira Women s Health inc 385.61%$ 385.609 millions
Intercure Ltd 318.38%$ 318.385 millions
Vireo Growth Inc.317.81%$ 317.813 millions
Cormedix Inc 312.10%$ 312.097 millions
Galapagos Nv303.50%$ 303.502 millions
Insmed Inc287.83%$ 287.825 millions
Tscan Therapeutics Inc 286.02%$ 286.015 millions
Beam Therapeutics Inc 279.52%$ 279.516 millions
Meiragtx Holdings Plc252.33%$ 252.333 millions
Star Equity Holdings Inc 232.22%$ 232.220 millions
Ethema Health Corporation 228.03%$ 228.030 millions
Foghorn Therapeutics Inc 223.77%$ 223.775 millions
Madrigal Pharmaceuticals Inc 210.77%$ 210.766 millions
Biocryst Pharmaceuticals Inc 209.09%$ 209.087 millions
Prenetics Global Limited201.94%$ 201.941 millions
Prokidney Corp 196.05%$ 196.053 millions
Mesoblast Limited191.39%$ 191.393 millions
Northwest Biotherapeutics Inc190.91%$ 190.909 millions
Zevra Therapeutics Inc 183.36%$ 183.360 millions
Spero Therapeutics Inc 174.51%$ 174.508 millions
Taysha Gene Therapies Inc 171.27%$ 171.266 millions


About Galapagos Nv Revenue Growth Rates (GLPG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Galapagos Nv (CIK 1421876).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-035163
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Galapagos Nv’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.